Clinical Evaluation of Novel Biomarkers for Diagnosis, Therapy- Monitoring and Prognosis of Outcome in Patients With Septicemia
18 Years
N/A
Both
Sepsis, Bacteremia, Fungemia
Trial Information
Clinical Evaluation of Novel Biomarkers for Diagnosis, Therapy- Monitoring and Prognosis of Outcome in Patients With Septicemia
The two most common causative pathogens of septicemia (Escherichia coli and Staphylococcus
aureus) as well as cases of fungemia (Candida spp., Aspergillus spp., and others) will be
included in the first study group. At our hospital the estimated yearly cases of
bacteremia/fungemia (230 for Escherichia coli, 150 for Staphylococcus aureus, and 50 for
fungi) will be included in the first study group. Furthermore, the two biomarkers will be
determined in 70 cases of septicemia with other bacterial pathogens and sepsis due to viral
pathogens or viremia for evaluation of further clinical impact of these two biomarkers.
Inclusion Criteria:
- Patients above 18 years
Exclusion Criteria:
- Patients < 18 years
Type of Study:
Observational
Study Design:
Observational Model: Cohort, Time Perspective: Prospective
Outcome Measure:
prognostic value of biomarkers in bacteremia
Outcome Time Frame:
2 years
Safety Issue:
No
Principal Investigator
Martin Hoenigl, MD
Investigator Role:
Principal Investigator
Investigator Affiliation:
Medical University of Graz
Authority:
Austria: Ethikkommission
Study ID:
21-469
NCT ID:
NCT01359891
Start Date:
November 2010
Completion Date:
June 2014
Related Keywords:
- Sepsis
- Bacteremia
- Fungemia
- Bacteremia
- Sepsis
- Toxemia
- Fungemia
Name | Location |
|---|
